Please login to the form below

Not currently logged in
Email:
Password:

Chiesi

This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.

Moderna inks R&D agreements with Vertex and Chiesi

Moderna inks R&D agreements with Vertex and Chiesi

Moderna has agreed to separate deals with Vertex and Chiesi for research and development spanning cystic fibrosis (CF) therapies and pulmonary arterial hypertension (PAH). ... Prior to announcing the Vertex deal, Moderna revealed that it had come to a

Latest news

  • Chiesi launches new rare disease R&D division Chiesi launches new rare disease R&D division

    Chiesi acquired Lamzede when it bought Zymenex in 2013 – the drug is administered weekly as intravenous infusions and the works by replacing the missing or malfunctioning enzyme. ... identify opportunities for us to collaborate in research and patient

  • AZ builds case for its COPD triple as it chases GSK’s Trelegy AZ builds case for its COPD triple as it chases GSK’s Trelegy

    First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy is dosed just once per ... day. Privately-held company Chiesi doesn’t

  • Europe responding to gene therapy challenge, but picture remains fragmented Europe responding to gene therapy challenge, but picture remains fragmented

    Chiesi’s Holoclar is another groundbreaking ATMP, a stem cell replacement therapy for patients with the rare blindness condition limbal stem cell deficiency, which gained European approval in 2015. ... Giorgio Iotti, head of programme leadership and

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy and PT010 are dosed just

  • Chiesi targets patient adherence via mobile app Chiesi targets patient adherence via mobile app

    Patients using Chiesi’s app will be able to review their inhaler technique and can share this during their consultations with their HCPs. ... Tom Delahoyde, managing director of Chiesi LTD, said: “Our aim is to help HCPs to better support patients in

More from news
Approximately 15 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    GSK, AZ and Chiesi are each playing in this new market.

  • Deal Watch May 2016 Deal Watch May 2016

    911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.

  • Anticipating the future in healthcare Anticipating the future in healthcare

    The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not

  • Pharma deals during October 2012 Pharma deals during October 2012

    In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Frontera Group Frontera Group

    AbbVie. Actavis . Alimera Sciences. Allergan . Amgen. AstraZeneca. Bayer. Boehringer Ingelheim. Chiesi.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics